Drugs Acting on the Renin-angiotensin System and SARS-CoV-2

Overview

Journal Drug Discov Today

Specialty Pharmacology

Date 2021 Jan 24

PMID 33486116

Citations 24

Authors

Antonio Vitiello

Chiara Pelliccia

Francesco Ferrara

Affiliations

Soon will be listed here.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing global Coronavirus 2019 (COVID-19) pandemic, resulting in thousands of deaths worldwide and representing a health challenge with few precedents in human history. Angiotensin-converting enzyme 2 (ACE-2) facilitates the access of SARS-CoV-2 to cells. Therapeutic agents acting on the renin-angiotensin system (RAS) might be able to modulate the concentration of ACE-2 and the various components of the system. Here, we discuss current pharmacological, molecular, and clinical evidence to investigate whether drugs acting on RAS with modulation of the ACE-2 concentration have added value in combating SARS-CoV-2 infection. We also highlight the possible deleterious action of the ACE/Ang-II/AT-1r axis and possible beneficial role of the ACE-2/Ang 1-7/MasR axis in acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2, discussing the possibility of addressing the various RAS components with drug treatments to improve clinical outcomes.

Citing Articles

Significance of nitrosative stress and glycoxidation products in the diagnosis of COVID-19.

Wolszczak-Biedrzycka B, Dorf J, Matowicka-Karna J, Wojewodzka-Zelezniakowicz M, Zukowski P, Zalewska A Sci Rep. 2024; 14(1):9198.

PMID: 38649417 PMC: 11035544. DOI: 10.1038/s41598-024-59876-w.

The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review.

Vitiello A, Sabbatucci M, Silenzi A, Capuano A, Rossi F, Zovi A Respir Res. 2023; 24(1):278.

PMID: 37957647 PMC: 10644493. DOI: 10.1186/s12931-023-02593-1.

The direct correlation between microbiota and SARS-CoV-2 infectious disease.

Vitiello A, Ferrara F, Zovi A Inflammopharmacology. 2023; 31(2):603-610.

PMID: 36725821 PMC: 9891758. DOI: 10.1007/s10787-023-01145-9.

Effects of Vitamin D on the Renin-Angiotensin System and Acute Childhood Pneumonia.

Zovi A, Ferrara F, Pasquinucci R, Nava L, Vitiello A, Arrigoni R Antibiotics (Basel). 2022; 11(11).

PMID: 36358201 PMC: 9686887. DOI: 10.3390/antibiotics11111545.

Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions.

Vitiello A, Zovi A, Trama U, Ferrara F Herz. 2022; 48(5):372-375.

PMID: 36331568 PMC: 9638345. DOI: 10.1007/s00059-022-05142-6.

References

Reynolds H, Adhikari S, Pulgarin C, Troxel A, Iturrate E, Johnson S . Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020; 382(25):2441-2448. PMC: 7206932. DOI: 10.1056/NEJMoa2008975. View

Mourad J, Levy B . Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nat Rev Cardiol. 2020; 17(5):313. PMC: 7104419. DOI: 10.1038/s41569-020-0368-x. View

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N . A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000; 87(5):E1-9. DOI: 10.1161/01.res.87.5.e1. View

Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G . Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020; 382(25):2431-2440. PMC: 7206933. DOI: 10.1056/NEJMoa2006923. View

Tipnis S, Hooper N, Hyde R, Karran E, Christie G, Turner A . A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000; 275(43):33238-43. DOI: 10.1074/jbc.M002615200. View

Magalhaes G, Rodrigues-Machado M, Motta-Santos D, Silva A, Caliari M, Prata L . Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol. 2015; 172(9):2330-42. PMC: 4403097. DOI: 10.1111/bph.13057. View

Tan W, Liao W, Zhou S, Mei D, Wong W . Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol. 2017; 40:9-17. DOI: 10.1016/j.coph.2017.12.002. View

Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga A, White H . Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2019; 31(4):419-423. PMC: 6414001. DOI: 10.1080/08998280.2018.1499293. View

Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T . Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res. 2005; 97(9):946-53. DOI: 10.1161/01.RES.0000187500.24964.7A. View

10.

de Abajo F, Rodriguez-Martin S, Lerma V, Mejia-Abril G, Aguilar M, Garcia-Luque A . Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020; 395(10238):1705-1714. PMC: 7255214. DOI: 10.1016/S0140-6736(20)31030-8. View

11.

Flores-Munoz M, Smith N, Haggerty C, Milligan G, Nicklin S . Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol. 2010; 589(Pt 4):939-51. PMC: 3060371. DOI: 10.1113/jphysiol.2010.203075. View

12.

Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H . Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020; 92(6):595-601. PMC: 7228221. DOI: 10.1002/jmv.25726. View

13.

Recinos 3rd A, LeJeune W, Sun H, Lee C, Tieu B, Lu M . Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis. 2006; 194(1):125-33. PMC: 2196437. DOI: 10.1016/j.atherosclerosis.2006.10.013. View

14.

Ferrara F, De Rosa F, Vitiello A . Worldwide Recommendations and Therapies for Multiple Sclerosis: Are They Safe in the COVID-19 Pandemic Period?. SN Compr Clin Med. 2020; 2(8):1017-1018. PMC: 7319216. DOI: 10.1007/s42399-020-00375-0. View

15.

Fraga-Silva R, Pinheiro S, Goncalves A, Alenina N, Bader M, Santos R . The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med. 2007; 14(1-2):28-35. PMC: 2078558. DOI: 10.2119/2007-00073.Fraga-Silva. View

16.

Kreutz R, Algharably E, Azizi M, Dobrowolski P, Guzik T, Januszewicz A . Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020; 116(10):1688-1699. PMC: 7184480. DOI: 10.1093/cvr/cvaa097. View

17.

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View

18.

Soto M, Bang S, McCombs J, Rodgers K . Renin Angiotensin system-modifying therapies are associated with improved pulmonary health. Clin Diabetes Endocrinol. 2017; 3:6. PMC: 5488416. DOI: 10.1186/s40842-017-0044-1. View

19.

Fraga-Silva R, Costa-Fraga F, De Sousa F, Alenina N, Bader M, Sinisterra R . An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics (Sao Paulo). 2011; 66(5):837-41. PMC: 3109384. DOI: 10.1590/s1807-59322011000500021. View

20.

Zhong J, Ye J, Jin H, Yu X, Yu H, Zhu D . Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept. 2010; 166(1-3):90-7. DOI: 10.1016/j.regpep.2010.09.005. View